Applications

1762 – Amendment to HER-2 MBS item to allow for trastuzumab deruxtecan for the treatment of patients with metastatic gastric or gastroesophageal junction adenocarcinoma

Find out about the service or technology in application 1762 and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input, and the outcome of the application when the MSAC process is complete.

  • Status Assessment
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Open
  • Outcome Pending

Application details

Applicant

Astrazeneca Pty Ltd

Reason for application

Amend MBS item.

Service or technology in this application

HER2 expression is a prognostic biomarker that is routinely screened in Australian clinical practice in patients with metastatic gastric or GEJ adenocarcinoma to determine eligibility to trastuzumab (first line treatment). HER2 testing for access to trastuzumab in metastatic gastric cancer is currently funded on the MBS.

Type: Investigative therapy

Medical condition this application addresses

Gastric and GEJ adenocarcinomas are the fifth most common cancers and fourth leading cause of cancer deaths worldwide, affecting both men and women. There were approximately 1 million incident cases and more than 769 000 associated deaths in 2020. (Sung H 2020) In Australia, the estimated incidence of gastric cancer diagnosed in 2022 was 2,572 patients (1,661 males + 911 females) with an overall five-year survival rate (2014-2018) of 37%. (Cancer Australia, AIHW). Approximately one in five gastric and GEJ adenocarcinomas are HER2-positive: an aggressive subtype that correlates with poor outcomes. (Iqbal N, 2014, ACS 2020).

Consultation survey and deadlines

The following consultation deadlines apply:

  • Pre-PASC consultation deadline: Expedited - bypassing PASC
  • Pre-MSAC consultation deadline: Friday 14 February 2025 11:59 pm AEDT

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

Meetings to consider this application

This application will be considered at the following meetings:

  • PASC meeting: Bypassing PASC
  • ESC meeting: Bypassing ESC
  • MSAC meeting: 3 to 4 April 2025

Find out more about our meetings.

Outcome details

The outcome of this application is pending.

More information

Find out more about: